Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera
- PMID: 21939712
- PMCID: PMC3359499
- DOI: 10.1016/j.vaccine.2011.09.021
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera
Abstract
The majority of cervical cancers are associated with infection by one or more Human Papillomavirus (HPV) types from just two distinct Alpha-Papillomavirus species groups, A7 and A9. The extent to which the current HPV16/18 vaccines will protect against other genetically related HPV types is of interest to inform vaccine implementation, cervical disease surveillance and the development of second generation HPV vaccines. The aim of this study was to determine the frequency and titer of neutralizing antibodies against a range of A7 (18, 39, 45, 59, 68) and A9 (16, 31, 33, 35, 52, 58) HPV types using sera from individuals immunized with the bivalent HPV vaccine within the school-based, UK national HPV immunization programme. Serum samples were collected from 69 girls aged 13-14 years, a median 5.9 months (inter-quartile range, IQR, 5.7-6.0) after their third vaccine dose. Cross-neutralizing antibodies against HPV31, HPV33, HPV35 and HPV45 were common and strongly associated with the titer for the related vaccine-type, but were considerably lower (<1%) than their related vaccine type-specific response. The low prevalence of these HPV types in the population and the ages within the study cohort suggest these responses are due to vaccination. It is unclear whether such low levels of neutralizing antibodies would be sufficient to protect at the site of infection in the absence of other immune effectors but the coincidence with HPV types reported from efficacy studies is intriguing. The utility of neutralizing antibodies as surrogate markers of protection remains to be determined.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures

Similar articles
-
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15. Vaccine. 2014. PMID: 24440205 Free PMC article.
-
Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.Vaccine. 2014 Sep 15;32(41):5357-62. doi: 10.1016/j.vaccine.2014.07.014. Epub 2014 Jul 18. Vaccine. 2014. PMID: 25045814
-
Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.PLoS One. 2015 Oct 23;10(10):e0140926. doi: 10.1371/journal.pone.0140926. eCollection 2015. PLoS One. 2015. PMID: 26495976 Free PMC article.
-
Developments in L2-based human papillomavirus (HPV) vaccines.Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Virus Res. 2017. PMID: 27889616 Free PMC article. Review.
-
Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.J Med Virol. 2013 Aug;85(8):1379-85. doi: 10.1002/jmv.23616. Epub 2013 May 30. J Med Virol. 2013. PMID: 23722396 Review.
Cited by
-
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Infect Genet Evol. 2013 Aug;18:151-9. doi: 10.1016/j.meegid.2013.05.013. Epub 2013 May 27. Infect Genet Evol. 2013. PMID: 23722024 Free PMC article.
-
Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.J Virol. 2015 Aug;89(15):7748-57. doi: 10.1128/JVI.00842-15. Epub 2015 May 20. J Virol. 2015. PMID: 25995264 Free PMC article.
-
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013. PLoS One. 2013. PMID: 23650505 Free PMC article. Clinical Trial.
-
Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.J Infect Dis. 2016 Mar 15;213(6):939-47. doi: 10.1093/infdis/jiv519. Epub 2015 Oct 30. J Infect Dis. 2016. PMID: 26518044 Free PMC article. Clinical Trial.
-
Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.PLoS One. 2013 Sep 18;8(9):e74797. doi: 10.1371/journal.pone.0074797. eCollection 2013. PLoS One. 2013. PMID: 24058629 Free PMC article.
References
-
- Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527. - PubMed
-
- Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2010;128(4):927–935. - PubMed
-
- Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314. - PubMed
-
- Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009;2(10):868–878. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials